Sugi Predict

Sugi Predict / Compounds / SCHEMBL9801877

SCHEMBL9801877

SCHEMBL9801877

OCCCCN1CCN(CCO)CC1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 2/20 0.52
▸ KDM4E B2RXH2 1/20 0.52
▸ HRH3 Q9Y5N1 2/20 0.43
▸ KMT2A Q03164 4/20 0.43
▸ LMNA P02545 2/20 0.43
▸ HTT P42858 1/20 0.43
▸ CHRM2 P08172 1/20 0.43
▸ HTR1A P08908 1/20 0.43
▸ ADRA2A P08913 1/20 0.43
▸ CHRM1 P11229 1/20 0.43
▸ DRD2 P14416 1/20 0.43
▸ ADRA2B P18089 1/20 0.43
▸ ADRA2C P18825 1/20 0.43
▸ DRD1 P21728 1/20 0.43
▸ PTGS1 P23219 1/20 0.43
▸ SLC6A2 P23975 1/20 0.43
▸ HTR2A P28223 1/20 0.43
▸ SLC6A4 P31645 1/20 0.43
▸ ADRA1A P35348 1/20 0.43
▸ HRH1 P35367 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11483699 0.94 — —
SCHEMBL1314968 0.92 ALDH1A1 (0.54) ALDH1A1KDM4EHRH3KMT2ALMNA
SCHEMBL11486700 0.92 HRH3 (0.52) ALDH1A1KDM4EHRH3KCNH2PAOX
SCHEMBL22911174 0.92 ALDH1A1 (0.54) ALDH1A1KDM4EHRH3KMT2ALMNA
SCHEMBL11484221 0.92 — —
SCHEMBL11484139 0.92 HRH3 (0.52) ALDH1A1KDM4EHRH3KCNH2PAOX
SCHEMBL11482886 0.92 HRH3 (0.52) ALDH1A1KDM4EHRH3KCNH2PAOX
SCHEMBL11899867 0.92 HRH3 (0.52) ALDH1A1KDM4EHRH3KCNH2PAOX
Methane SCHEMBL10746573 0.89 ALDH1A1 (0.52) ALDH1A1KDM4EHRH3KMT2ALMNA
SCHEMBL972563 0.85 KDM4E (0.46) ALDH1A1KDM4EHRH3KMT2ALMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12036209-B2 Compounds and methods for the targeted degradation of Interleukin-1 receptor-associated kinase 4 polypeptides ARVINAS OPERATIONS, INC. (US) 2024-07-16 — — US disclosed
US-10723717-B2 Compounds and methods for the targeted degradation of rapidly accelerated fibrosarcoma polypeptides ARVINAS OPERATIONS, INC. (US) 2020-07-28 — — US disclosed
US-4992150-A Telomer with alpha-olefin;oil and fuel additive NIPPON OIL CO, LTD. (JP) 1991-02-12 — — US disclosed
US-4455168-A CONTAINING A HETEROCYCLIC, HYDROXY AMINE OR AMIDE RICOH COMPANY, LTD. (JP) 1984-06-19 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12036209-B2 Compounds and methods for the targeted degradation of Interleukin-1 receptor-associated kinase 4 polypeptides IRAK1, IRAK4, IRAK2 ALDH1A1 2211/4885KDM4E 1450/4885HRH3 2941/4885
US-10723717-B2 Compounds and methods for the targeted degradation of rapidly accelerated fibrosarcoma polypeptides CRBN, ARAF, VHL ALDH1A1 2833/4885KDM4E 3116/4885HRH3 3690/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.